Home / Intelligence / Webinars / How to Generate Evidence to Drive Differentiation for Your Asset in a Competitive Market
Available On Demand
Demonstrating and communicating the value story to clinicians and payers is critical for successful commercialization, but there are many scenarios where new products may struggle to differentiate themselves. If you have a better mousetrap, how do you demonstrate value to support pricing, access, adoption and reimbursement?
The HEOR Evidence Strategy team at Trinity Life Sciences will conduct a webinar to explore this important question and share several case studies where we worked with companies facing this challenge. We will also discuss how evidence generation needs vary across the product life cycle, what is needed in preparation for launch and the opportunities and challenges in evidence dissemination.
Come learn with the Trinity Evidence Strategy team!
Key Topics for Case Studies
- Differentiation based on safety and tolerability when efficacy is similar
- Defining and illustrating new value drivers in a market with multiple therapeutics with similar mechanisms of action
- Demonstrating how product characteristics beyond efficacy and safety influence patient preferences and adherence
Complete the form below to watch the on-demand webinar.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
White Papers
Measuring the Impact of Field Medical Affairs
Demonstrating the value of Field Medical Affairs has, to date, been a challenge due to its qualitative and non-promotional nature. Traditional, activity-based metrics have missed the mark on translating Field Medical Affairs activities to tangible milestones, such as changes in HCP perception, HCP advocacy or closing critical care gaps that impact overall patient outcomes. When […]
Read More
White Papers
Evidence Generation in a Post-IRA World
Since the passage of the Inflation Reduction Act (IRA) in 2022, the pharmaceutical industry has significantly altered how they approach and plan for evidence generation activities to best support product launches and pricing and access negotiations. Leading life science companies are taking proactive steps to adjust how and when they develop evidence and how they […]
Read More
White Papers
Annual State of Global Market Access
In 2023, the life sciences industry saw key therapeutic advances in sickle cell disease, obesity/weight management, and Duchenne muscular dystrophy, among others, and the continued approvals of therapies with cutting edge mechanisms, including the first CRISPR therapy. While 2022 was characterized by accelerated development processes and the rapid evolution of therapeutic standards, 2023 featured increased […]
Read More